BiomX

Company Overview

Snapshot

Founded in May 2015 by Eran Elinav, Rotem Sorek, and Tim Lu, BiomX operates with 51–200 employees. The company has raised a total of $146.5M across 11 funding rounds from 15 investors. In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, expanding its presence in security and defense markets.

Business overview

BiomX is a clinical-stage microbiome company focused on developing natural and engineered phage cocktails to target and destroy bacteria implicated in chronic diseases such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. The company leverages computational and synthetic biology platforms, incorporating research from the Weizmann Institute of Science and the Massachusetts Institute of Technology. Beyond its core therapeutic focus, BiomX is expanding into security and defense markets through its X Security & Defense division, identifying and commercializing technologies to address operational needs in national security, emergency response, and critical infrastructure protection.

Strategic signal

In April 2026, BiomX significantly diversified its strategic focus by acquiring Zorronet, an autonomous AI command-and-control platform. This move signals a deliberate expansion beyond its traditional microbiome therapeutics into the defense and security sectors, indicating a potential pivot or broadening of its business model to leverage AI for national security and critical infrastructure protection. This acquisition suggests BiomX is pursuing new revenue streams and applications for its technological capabilities.

Company Intelligence Q&A

What was a significant recent acquisition by BiomX?

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, to expand its presence in security and defense markets.

What was the latest update on the BX004 clinical trial for cystic fibrosis?

In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial evaluating BX004 for the treatment of chronic pulmonary infections in patients with cystic fibrosis.

When did BiomX become a public company?

BiomX became public on the NYSE in November 2019 through a merger with Chardan Healthcare Acquisition Corp.

What was the nature of the collaboration with Boehringer Ingelheim?

In September 2020, BiomX entered a collaboration with Boehringer Ingelheim with the goal of discovering microbiome-based biomarkers for Inflammatory Bowel Disease.